GSK has walked away from a leading Wave Therapeutics RNA‑editing program, a move Wave characterized as reflecting its ability to advance the rare‑disease candidate more quickly outside the Big Pharma partnership. Wave suggested the decision was strategic rather than scientific and signaled plans to press forward with its RNA‑editing technology independently. The split illustrates the commercial and operational frictions that can arise in pioneering modalities like in‑vivo RNA editing as companies prioritize speed, control, and rare‑disease positioning.